BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24428673)

  • 1. Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.
    Rizzieri DA; Johnson JL; Byrd JC; Lozanski G; Blum KA; Powell BL; Shea TC; Nattam S; Hoke E; Cheson BD; Larson RA;
    Br J Haematol; 2014 Apr; 165(1):102-11. PubMed ID: 24428673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas.
    Kujawski LA; Longo WL; Williams EC; Turman NJ; Brandt N; Mosher DF; Eickhoff JC; Kahl BS
    Cancer Invest; 2007 Mar; 25(2):87-93. PubMed ID: 17453819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as support.
    Cabanillas F; Cotto M; Liboy I; Rivera E; Pavia OA; Bruno M
    Leuk Lymphoma; 2012 Oct; 53(10):1929-33. PubMed ID: 22448918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.
    Ribrag V; Koscielny S; Bosq J; Leguay T; Casasnovas O; Fornecker LM; Recher C; Ghesquieres H; Morschhauser F; Girault S; Le Gouill S; Ojeda-Uribe M; Mariette C; Cornillon J; Cartron G; Verge V; Chassagne-Clément C; Dombret H; Coiffier B; Lamy T; Tilly H; Salles G
    Lancet; 2016 Jun; 387(10036):2402-11. PubMed ID: 27080498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.
    Fayad L; Thomas D; Romaguera J
    Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 2():S57-62. PubMed ID: 18284717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.
    Evens AM; Carson KR; Kolesar J; Nabhan C; Helenowski I; Islam N; Jovanovic B; Barr PM; Caimi PF; Gregory SA; Gordon LI
    Ann Oncol; 2013 Dec; 24(12):3076-81. PubMed ID: 24146219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia.
    Todeschini G; Bonifacio M; Tecchio C; Balter R; Carli G; Stefani PM; Adami F; Zamò A; Dei Tos AP; Marino F; Gherlinzoni F; Marradi P; Semenzato G; Pizzolo G
    Am J Hematol; 2012 Jan; 87(1):22-5. PubMed ID: 22086870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma.
    Corazzelli G; Frigeri F; Russo F; Frairia C; Arcamone M; Esposito G; De Chiara A; Morelli E; Capobianco G; Becchimanzi C; Volzone F; Saggese M; Marcacci G; De Filippi R; Vitolo U; Pinto A
    Br J Haematol; 2012 Jan; 156(2):234-44. PubMed ID: 22098541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.
    Maruyama D; Watanabe T; Maeshima AM; Nomoto J; Taniguchi H; Azuma T; Mori M; Munakata W; Kim SW; Kobayashi Y; Matsuno Y; Tobinai K
    Int J Hematol; 2010 Dec; 92(5):732-43. PubMed ID: 21120644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia.
    Kasamon YL; Brodsky RA; Borowitz MJ; Ambinder RF; Crilley PA; Cho SY; Tsai HL; Smith BD; Gladstone DE; Carraway HE; Huff CA; Matsui WH; Bolaños-Meade J; Jones RJ; Swinnen LJ
    Leuk Lymphoma; 2013 Mar; 54(3):483-90. PubMed ID: 22835045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients.
    Xicoy B; Ribera JM; Müller M; García O; Hoffmann C; Oriol A; Hentrich M; Grande C; Wasmuth JC; Esteve J; van Lunzen J; Del Potro E; Knechten H; Brunet S; Mayr C; Escoda L; Schommers P; Alonso N; Vall-Llovera F; Pérez M; Morgades M; González J; Fernández A; Thoden J; Gökbuget N; Hoelzer D; Fätkenheuer G; Wyen C;
    Leuk Lymphoma; 2014 Oct; 55(10):2341-8. PubMed ID: 24397614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
    Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
    Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial.
    Hoelzer D; Walewski J; Döhner H; Viardot A; Hiddemann W; Spiekermann K; Serve H; Dührsen U; Hüttmann A; Thiel E; Dengler J; Kneba M; Schaich M; Schmidt-Wolf IG; Beck J; Hertenstein B; Reichle A; Domanska-Czyz K; Fietkau R; Horst HA; Rieder H; Schwartz S; Burmeister T; Gökbuget N;
    Blood; 2014 Dec; 124(26):3870-9. PubMed ID: 25359988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Burkitt lymphoma in children and adults: Lessons from Africa.
    Magrath IT
    Curr Hematol Malig Rep; 2006 Dec; 1(4):230-40. PubMed ID: 20425318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of advanced-stage mature B-cell lymphoma and leukemia in children and adolescents with rituximab and reduced intensity induction chemotherapy (B-NHL 2004M protocol): the results of a multicenter study.
    Samochatova EV; Maschan AA; Shelikhova LN; Myakova NV; Belogurova MB; Khlebnikova OP; Shamardina AV; Ryskal OV; Roumiantseva JV; Konovalov DM; Dubrovina ME; Rumyantsev AG
    J Pediatr Hematol Oncol; 2014 Jul; 36(5):395-401. PubMed ID: 23823112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long term efficacy of COPADM regimen in the treatment of 20 patients with Burkitt lymphoma].
    Yang D; Wang P; Chen J; Li CX; Zhang Y; Chen XC; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2018 Aug; 39(8):645-649. PubMed ID: 30180465
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of the GMALL-B-ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin-lymphomas with or without CNS involvement.
    Sakarou M; Eisele L; Dührsen U; Hüttmann A
    Eur J Haematol; 2019 Mar; 102(3):241-250. PubMed ID: 30471148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.
    Roschewski M; Dunleavy K; Abramson JS; Powell BL; Link BK; Patel P; Bierman PJ; Jagadeesh D; Mitsuyasu RT; Peace D; Watson PR; Hanna WT; Melani C; Lucas AN; Steinberg SM; Pittaluga S; Jaffe ES; Friedberg JW; Kahl BS; Little RF; Bartlett NL; Fanale MA; Noy A; Wilson WH
    J Clin Oncol; 2020 Aug; 38(22):2519-2529. PubMed ID: 32453640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program.
    Intermesoli T; Rambaldi A; Rossi G; Delaini F; Romani C; Pogliani EM; Pagani C; Angelucci E; Terruzzi E; Levis A; Cassibba V; Mattei D; Gianfaldoni G; Scattolin AM; Di Bona E; Oldani E; Parolini M; Gökbuget N; Bassan R
    Haematologica; 2013 Nov; 98(11):1718-25. PubMed ID: 23753030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of the efficacy of CCCG-97 and BFM-90 protocols in the treatment for children with mature B-cell non-Hodgkin's lymphoma].
    Meng JH; Gao YJ; Lu FJ; Zhai XW; Wang HS; Li J
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):222-7. PubMed ID: 22780979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.